PMA device
EXOGEN® Ultrasound Bone Healing System
Bioventus, LLC · Stimulator, Bone Growth, Non-Invasive (LOF, Class II) · First FDA decision Dec 20, 2019, newest Dec 21, 2023Degenerative disc disease and spinal stenosisFractures and orthopedic trauma
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
5
Naming "EXOGEN"
MAUDE reports
31
Brand "EXOGEN", since 2015
PubMed studies
178
Mentioning "EXOGEN"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EXOGEN® Ultrasound Bone Healing System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- EXOGEN® Ultrasound Bone Healing SystemPMA supplement
P900009-S049 · Decided Dec 21, 2023 · 154 days after receipt · Normal 180 Day Track No User Fee
Device type: Stimulator, bone growth, non-invasive (LOF) · Orthopedic Surgery
- EXOGEN Ultrasound Bone Healing SystemPMA supplement
P900009-S047 · Decided Aug 31, 2021 · 98 days after receipt · Normal 180 Day Track
Device type: Stimulator, bone growth, non-invasive (LOF) · Orthopedic Surgery
- Exogen Ultrasound Bone Healing SystemPMA supplement
P900009-S044 · Decided Dec 20, 2019 · 178 days after receipt · Normal 180 Day Track
Device type: Stimulator, bone growth, non-invasive (LOF) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "EXOGEN", any status and sponsor, newest update first.
- Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at RiskCompleted
Bioventus LLCNot on our public-company list
NCT03382483 · 12,387 participants · Start Oct 16, 2017 · Primary completion May 26, 2020
Device: Low intensity pulsed ultrasound · For: Mitigation of Fracture Non-union in Patients at Risk
Sites: Jericho, New York
- Scaphoid Non-union and Low-intensity Pulsed Ultrasound TrialPivotal-lookingStatus unknown
University of CalgaryAcademic, hospital or other
NCT02383160 · 154 participants (planned) · Start Sep 2014 · Primary completion Dec 31, 2022
Device: Bioventus Exogen 4000: Low-intensity pulsed ultrasound; Sham device · For: Nonunion of Fracture of Scaphoid Bone; Fractures, Ununited
Sites: Calgary, Canada; Vancouver, Canada; Winnipeg, Canada · 6 sites in all
- Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar SurgeryPivotal-lookingTerminated
Bioventus LLCNot on our public-company list
NCT00744861 · 328 participants · Start Sep 2008 · Primary completion May 2012
Device: Exospine sham; Exospine and 2 more · For: Lumbar Degenerative Disc Disease
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EXOGEN", and for the whole product code for context.
This brand
31 reports: 1 malfunction, 27 injury, 1 death
Whole product code LOF
1,378 reports: 17 malfunction, 1,353 injury, 4 death
Newest reports for this brand
- EXOGEN ULTRASOUND BONE HEALING SYSTEMMalfunction
MW5114799 · Received Feb 8, 2023 · Event dated Aug 24, 2022
Device type: Stimulator, Bone Growth, Non-Invasive (LOF)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Nonunion/Delayed-union Bone Fracture
MW5112171 · Received Sep 20, 2022 · Event dated Sep 13, 2022
Device type: Stimulator, Bone Growth, Non-Invasive (LOF)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Blister
3010203571-2021-00009 · Received Oct 8, 2021 · Event dated Dec 1, 2020
Device type: Stimulator, Bone Growth, Non-Invasive (LOF)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Unspecified Infection; Pain
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- EXOGEN Ultrasound Coupling GelTerminated
Z-0810-2021 · Started Dec 17, 2020
Reason given: Product may contain white particulates that are microbial in nature.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Stimulator, Bone Growth, Non-Invasive (LOF)
Z-1695-2009 · Started Jun 5, 2009 · Posted by FDA Aug 4, 2009
Reason given: Problems with transducer may result in a reduced ultrasound output.
Cause as FDA categorized it: Other · Device type: Stimulator, Ultrasound And Muscle, For Use Other Than Applying Therapeutic Deep (LPQ)
Z-1696-2009 · Started Jun 5, 2009 · Posted by FDA Aug 4, 2009
Reason given: Problems with transducer may result in a reduced ultrasound output.
Cause as FDA categorized it: Other · Device type: Stimulator, Ultrasound And Muscle, For Use Other Than Applying Therapeutic Deep (LPQ)
Published research
The most relevant PubMed records for "EXOGEN"[tiab]. The summary above synthesizes these.
- Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept.
Hertz L, Flormann D, Birnbaumer L, et al. · Blood Adv · 2023Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't
- EXOGEN Mitigates Risk of Fifth Metatarsal Fracture Nonunion: Results of a Novel Real-World Clinical Study.
Zura R, Anderson RB, Ahmed SS, et al. · Foot Ankle Orthop · 2022
- Pitfalls preventing bone union with EXOGEN Low-Intensity Pulsed Ultrasound.
Hughes LD, Khudr J, Gee E, et al. · SICOT J · 2022
- Exogen Hairs in Women with and without Hair Loss.
Guarrera M, Rebora A · Skin Appendage Disord · 2017
- Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss.
Natarelli N, Gahoonia N, Sivamani RK · J Clin Med · 2023Review
- Telogen effluvium revisited.
Rebora A · G Ital Dermatol Venereol · 2014Review
- The neuroprotective effect of exogen melatonin upon fetal hippocampus damage caused by high-dose caffeine administration in pregnant rats.
Köse Y, Şirin C, Turgut AÇ, et al. · Int J Dev Neurosci · 2024
- Roles of Msx2 in exogen control: modulating the stem cell niche during the transition from hair shedding to regeneration.
Chen Q, Jea WC, Jiang TX, et al. · J Adv Res · 2026Research Support, Non-U.S. Gov't
- From telogen to exogen: mechanisms underlying formation and subsequent loss of the hair club fiber.
Higgins CA, Westgate GE, Jahoda CA · J Invest Dermatol · 2009Research Support, Non-U.S. Gov't, Review
- Exogen is an active, separately controlled phase of the hair growth cycle.
Stenn K · J Am Acad Dermatol · 2005Comment, Letter
- Dietary Vitamin A Impacts Refractory Telogen.
Suo L, VanBuren C, Hovland ED, et al. · Front Cell Dev Biol · 2021
- Exogen hair characterization in human scalp.
Van Neste D, Leroy T, Conil S · Skin Res Technol · 2007Clinical Trial
Other devices of this type
Also filed under product code LOF.
- Physio-StimOrthofix, Inc. · PMA 2017
- Cervical-StimOrthofix, Inc. · PMA 2016
- ActaStim-STheragen, Inc. · PMA 2026
- Biomet Ebi Bone Healing SystemAhp Eos Buyer, Inc. · PMA 2013
- OL1000/OL1000 Sc and Spinalogic Bone Growth StimulatorsDjo, LLC · PMA 2012
- AccelStimOrthofix US, LLC · PMA 2025
- ManaFuseEnovis · PMA 2025
- Xstim Spine Fusion StimulatorXstim, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.